For UAE, Kuwait, Bahrain, Qatar and Oman Healthcare Professionals Only
WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Discover the powerful efficacy of WAINUA
Learn more about once-monthly self-administration
See how WAINUA targets TTR at the source
FOOTNOTES
hATTR, hereditary transthyretin-mediated amyloidosis; mNIS+7, modified Neuropathy Impairment Score +7; Norfolk QoL-DN, Norfolk Quality of Life-Diabetic Neuropathy; TTR, transthyretin.
REFERENCE
- 1. WAINUATM (eplontersen) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP: 2024.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
- Reduced Serum Vitamin A Levels and Recommended Supplementation WAINUA leads to a decrease in serum vitamin A levels. Supplement with recommended daily allowance of vitamin A. Refer patient to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur.
ADVERSE REACTIONS
Most common adverse reactions (≥9% in WAINUA-treated patients) were vitamin A decreased (15%) and vomiting (9%).
INDICATION
WAINUA injection, for subcutaneous use, 45 mg is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Loading......
Modal Window Component Section Begins
Modal Window Component Section Ends